<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05099276</url>
  </required_header>
  <id_info>
    <org_study_id>21-08313-FB</org_study_id>
    <nct_id>NCT05099276</nct_id>
  </id_info>
  <brief_title>Extended Postoperative Oral Tranexamic Acid in Knee Replacement</brief_title>
  <official_title>Extended Postoperative Tranexamic Acid Use in Primary Total Knee Arthroplasty: A Prospective, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Campbell Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Campbell Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A comparison of outcomes between use of oral tranexamic acid as compared to oral placebo in&#xD;
      the first days after total knee replacement will be made to determine impact on clinical&#xD;
      indications and patient reported outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Significant blood loss occurs during total knee arthroplasty (TKA) which can lead to adverse&#xD;
      outcomes including need for blood transfusion as well as increased local tissue swelling and&#xD;
      ecchymosis which can inhibit post-operative recovery. Tranexamic acid (TXA), an inhibitor of&#xD;
      fibrinolysis, has been shown to be a safe and effective drug for reducing blood loss during&#xD;
      and after TKA. The use of TXA intraoperatively has been associated with higher postoperative&#xD;
      hemoglobin levels and a reduction in postoperative blood transfusion rates. Administration of&#xD;
      TXA in TKA has also been associated with improved clinical outcome measures including&#xD;
      decreased rate of periprosthetic joint infection, decreased length of stay, and increased&#xD;
      postoperative range of motion and early ambulation distances. However, there remains a wide&#xD;
      variance in the route of administration, dosage, and timing of TXA use among treatment&#xD;
      protocols in TKA. Previous studies have evaluated outcomes with the addition of&#xD;
      post-operative TXA dosing to standard pre-operative and intra-operative intravenous (IV)&#xD;
      doses. This study will investigate patient outcomes following a standardized post-operative&#xD;
      oral TXA protocol as compared to oral placebo for three doses over day of surgery, postop day&#xD;
      one and postop day two after TKA.&#xD;
&#xD;
      Following written consent documentation, Subjects will be randomized and blinded to&#xD;
      randomization assignment until completion of study to either the oral TXA group or oral&#xD;
      placebo group. The study medication will be distributed with the Subject's name with&#xD;
      instructions for use in the post-anesthesia unit (PACU). The first dose will be administered&#xD;
      in PACU with subsequent doses to be taken at home on postop day one and postop day two. TKA&#xD;
      will be completed in an ambulatory surgery center with discharge same day of surgery to home.&#xD;
&#xD;
      Outcome measures include: Hemoglobin, visual analog score, KOOS Jr (Knee injury and&#xD;
      osteoarthritis outcome score), range of motion, and incidence of treatment-emergent adverse&#xD;
      event at postoperative (POD) day 3, POD week 2, POD week 6, and POD week 12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Both oral TXA and oral placebo will be distributed to subjects in bottle marked with subject name and instructions for use following discharge from PACU.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>preoperative</time_frame>
    <description>Hemoglobin enables red cells to transport oxygen and carbon dioxide in the blood and is measured in grams per deciliter with normal ranges of 12.0 to 17.5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>postoperative hour 3</time_frame>
    <description>Hemoglobin enables red cells to transport oxygen and carbon dioxide in the blood and is measured in grams per deciliter with normal ranges of 12.0 to 17.5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>postoperative day 3</time_frame>
    <description>Hemoglobin enables red cells to transport oxygen and carbon dioxide in the blood and is measured in grams per deciliter with normal ranges of 12.0 to 17.5</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin level</measure>
    <time_frame>postoperative week 2</time_frame>
    <description>Hemoglobin enables red cells to transport oxygen and carbon dioxide in the blood and is measured in grams per deciliter with normal ranges of 12.0 to 17.5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Score</measure>
    <time_frame>preoperative</time_frame>
    <description>Patient reported pain score from 0 to 10 where 0 is no pain and 10 is the most pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Score</measure>
    <time_frame>postoperative hour 3</time_frame>
    <description>Patient reported pain score from 0 to 10 where 0 is no pain and 10 is the most pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Score</measure>
    <time_frame>postoperative week 2</time_frame>
    <description>Patient reported pain score from 0 to 10 where 0 is no pain and 10 is the most pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Score</measure>
    <time_frame>postoperative week 6</time_frame>
    <description>Patient reported pain score from 0 to 10 where 0 is no pain and 10 is the most pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Score</measure>
    <time_frame>postoperative week 12</time_frame>
    <description>Patient reported pain score from 0 to 10 where 0 is no pain and 10 is the most pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KOOS Jr Score</measure>
    <time_frame>preoperative</time_frame>
    <description>Patient reported outcome of how the knee feels from 0 to one 100 where 0 represents extreme problems and 100 represents no problems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KOOS Jr Score</measure>
    <time_frame>postoperative day 3</time_frame>
    <description>Patient reported outcome of how the knee feels from 0 to one 100 where 0 represents extreme problems and 100 represents no problems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KOOS Jr Score</measure>
    <time_frame>postoperative week 2</time_frame>
    <description>Patient reported outcome of how the knee feels from 0 to one 100 where 0 represents extreme problems and 100 represents no problems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KOOS Jr Score</measure>
    <time_frame>postoperative week 6</time_frame>
    <description>Patient reported outcome of how the knee feels from 0 to one 100 where 0 represents extreme problems and 100 represents no problems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KOOS Jr Score</measure>
    <time_frame>postoperative week 12</time_frame>
    <description>Patient reported outcome of how the knee feels from 0 to one 100 where 0 represents extreme problems and 100 represents no problems</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>range of motion of knee</measure>
    <time_frame>preoperative</time_frame>
    <description>clinical measurement of passive, pain-free range of motion of knee in degrees from 0 to 180 from maximum extension to maximum flexion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>range of motion of knee</measure>
    <time_frame>postoperative day 3</time_frame>
    <description>clinical measurement of passive, pain-free range of motion of knee in degrees from 0 to 180 from maximum extension to maximum flexion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>range of motion of knee</measure>
    <time_frame>postoperative week 2</time_frame>
    <description>clinical measurement of passive, pain-free range of motion of knee in degrees from 0 to 180 from maximum extension to maximum flexion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>range of motion of knee</measure>
    <time_frame>postoperative week 6</time_frame>
    <description>clinical measurement of passive, pain-free range of motion of knee in degrees from 0 to 180 from maximum extension to maximum flexion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>range of motion of knee</measure>
    <time_frame>postoperative week 12</time_frame>
    <description>clinical measurement of passive, pain-free range of motion of knee in degrees from 0 to 180 from maximum extension to maximum flexion</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of treatment-emergent adverse event</measure>
    <time_frame>postoperative day 3</time_frame>
    <description>monitoring for safety events</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of treatment-emergent adverse event</measure>
    <time_frame>postoperative week 2</time_frame>
    <description>monitoring for safety events</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of treatment-emergent adverse event</measure>
    <time_frame>postoperative week 6</time_frame>
    <description>monitoring for safety events</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of treatment-emergent adverse event</measure>
    <time_frame>postoperative week 12</time_frame>
    <description>monitoring for safety events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <condition>Blood Loss</condition>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Oral TXA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1,950 mg oral tranexmic acid (three capsules of 650 mg) administered in post-anesthesia care, postop day one and postop day two. Compounded by registered pharmacist and labeled with subject name and instructions for use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three capsules of cellulose administered in post-anesthesia care, postop day one and postop day two. Compounded by registered pharmacist and labeled with subject name and instructions for use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid Pill</intervention_name>
    <description>1950 mg tranexamic acid (three capsules) given in post-anesthesia room and three capsules for postop day one and three capsules for postop day two</description>
    <arm_group_label>Oral TXA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Three capsules of cellulose given in post-anesthesia room and three capsules for postop cay one and three capsules for postop day two</description>
    <arm_group_label>Oral placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary total knee replacement in ambulatory setting&#xD;
&#xD;
          -  Willing to participate&#xD;
&#xD;
          -  Physical therapy on site at Campbell Clinic Wolf River&#xD;
&#xD;
          -  Fluent in oral and written English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling to participate&#xD;
&#xD;
          -  Revision total knee replacement&#xD;
&#xD;
          -  Preoperative use of anticoagulants other than 81 mg aspirin&#xD;
&#xD;
          -  Previous history of thromboembolic event&#xD;
&#xD;
          -  Previous history of cancer other than non-melanoma skin cancers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus C Ford, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Campbell Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Donna Ashford, BSN</last_name>
    <phone>901-435-5711</phone>
    <email>dashford@campbell-foundation.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Margaret Knack</last_name>
    <phone>901-759-5413</phone>
    <email>mknack@campbell-foundation.org</email>
  </overall_contact_backup>
  <reference>
    <citation>Fillingham YA, Ramkumar DB, Jevsevar DS, Yates AJ, Shores P, Mullen K, Bini SA, Clarke HD, Schemitsch E, Johnson RL, Memtsoudis SG, Sayeed SA, Sah AP, Della Valle CJ. The Safety of Tranexamic Acid in Total Joint Arthroplasty: A Direct Meta-Analysis. J Arthroplasty. 2018 Oct;33(10):3070-3082.e1. doi: 10.1016/j.arth.2018.03.031. Epub 2018 Mar 22.</citation>
    <PMID>29699826</PMID>
  </reference>
  <results_reference>
    <citation>Rutherford RW, Jennings JM, Dennis DA. Enhancing Recovery After Total Knee Arthroplasty. Orthop Clin North Am. 2017 Oct;48(4):391-400. doi: 10.1016/j.ocl.2017.05.002. Epub 2017 Aug 8. Review.</citation>
    <PMID>28870300</PMID>
  </results_reference>
  <results_reference>
    <citation>Prasad N, Padmanabhan V, Mullaji A. Blood loss in total knee arthroplasty: an analysis of risk factors. Int Orthop. 2007 Feb;31(1):39-44. Epub 2006 Mar 28.</citation>
    <PMID>16568327</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim JK, Park JY, Lee DY, Ro DH, Han HS, Lee MC. Optimal dose of topical tranexamic acid considering efficacy and safety in total knee arthroplasty: a randomized controlled study. Knee Surg Sports Traumatol Arthrosc. 2021 Oct;29(10):3409-3417. doi: 10.1007/s00167-020-06241-9. Epub 2020 Aug 31.</citation>
    <PMID>32869124</PMID>
  </results_reference>
  <results_reference>
    <citation>Wu C, Tan C, Wang L. Higher doses of topical tranexamic acid safely improves immediate functional outcomes and reduces transfusion requirement in total knee arthroplasty. Arch Orthop Trauma Surg. 2020 Dec;140(12):2071-2075. doi: 10.1007/s00402-020-03591-4. Epub 2020 Aug 29.</citation>
    <PMID>32862267</PMID>
  </results_reference>
  <results_reference>
    <citation>Drain NP, Gobao VC, Bertolini DM, Smith C, Shah NB, Rothenberger SD, Dombrowski ME, O'Malley MJ, Klatt BA, Hamlin BR, Urish KL. Administration of Tranexamic Acid Improves Long-Term Outcomes in Total Knee Arthroplasty. J Arthroplasty. 2020 Jun;35(6S):S201-S206. doi: 10.1016/j.arth.2020.02.047. Epub 2020 Mar 4.</citation>
    <PMID>32209286</PMID>
  </results_reference>
  <results_reference>
    <citation>Grosso MJ, Trofa DP, Danoff JR, Hickernell TR, Murtaugh T, Lakra A, Geller JA. Tranexamic acid increases early perioperative functional outcomes after total knee arthroplasty. Arthroplast Today. 2017 Jun 29;4(1):74-77. doi: 10.1016/j.artd.2017.05.009. eCollection 2018 Mar.</citation>
    <PMID>29560399</PMID>
  </results_reference>
  <results_reference>
    <citation>Torkaman A, Rostami A, Sarshar MR, Akbari Aghdam H, Motaghi P, Yazdi H. The Efficacy of Intravenous Versus Topical Use of Tranexamic Acid in Reducing Blood Loss after Primary Total Knee Arthroplasty: A Randomized Clinical Trial. Arch Bone Jt Surg. 2020 May;8(3):363-367. doi: 10.22038/abjs.2020.40528.2099.</citation>
    <PMID>32766393</PMID>
  </results_reference>
  <results_reference>
    <citation>Lei Y, Xie J, Huang Q, Huang W, Pei F. Additional benefits of multiple-dose tranexamic acid to anti-fibrinolysis and anti-inflammation in total knee arthroplasty: a randomized controlled trial. Arch Orthop Trauma Surg. 2020 Aug;140(8):1087-1095. doi: 10.1007/s00402-020-03442-2. Epub 2020 Apr 6.</citation>
    <PMID>32253548</PMID>
  </results_reference>
  <results_reference>
    <citation>Pavenski K, Ward SE, Hare GMT, Freedman J, Pulendrarajah R, Pirani RA, Sheppard N, Vance C, White A, Lo N, Waddell JP, Ho A, Schemitsch EH, Kataoka M, Bogoch ER, Saini K, David Mazer C, Baker JE. A rationale for universal tranexamic acid in major joint arthroplasty: overall efficacy and impact of risk factors for transfusion. Transfusion. 2019 Jan;59(1):207-216. doi: 10.1111/trf.14995. Epub 2018 Nov 1.</citation>
    <PMID>30383292</PMID>
  </results_reference>
  <results_reference>
    <citation>Luo ZY, Wang HY, Wang D, Zhou K, Pei FX, Zhou ZK. Oral vs Intravenous vs Topical Tranexamic Acid in Primary Hip Arthroplasty: A Prospective, Randomized, Double-Blind, Controlled Study. J Arthroplasty. 2018 Mar;33(3):786-793. doi: 10.1016/j.arth.2017.09.062. Epub 2017 Oct 6.</citation>
    <PMID>29107495</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang HY, Wang L, Luo ZY, Wang D, Tang X, Zhou ZK, Pei FX. Intravenous and subsequent long-term oral tranexamic acid in enhanced-recovery primary total knee arthroplasty without the application of a tourniquet: a randomized placebo-controlled trial. BMC Musculoskelet Disord. 2019 Oct 25;20(1):478. doi: 10.1186/s12891-019-2885-5.</citation>
    <PMID>31653221</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang D, Wang HY, Luo ZY, Meng WK, Pei FX, Li Q, Zhou ZK, Zeng WN. Blood-conserving efficacy of multiple doses of oral tranexamic acid associated with an enhanced-recovery programme in primary total knee arthroplasty: a randomized controlled trial. Bone Joint J. 2018 Aug;100-B(8):1025-1032. doi: 10.1302/0301-620X.100B8.BJJ-2017-1598.R1.</citation>
    <PMID>30062946</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 11, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Campbell Clinic</investigator_affiliation>
    <investigator_full_name>Marcus C. Ford</investigator_full_name>
    <investigator_title>Research Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

